<!DOCTYPE html>
<html>
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
</head>
<body>
<div class="moz-cite-prefix">On 2/12/2024 5:29 PM, Wanda T. Kellar
via Pct wrote:<br>
</div>
<blockquote type="cite"
cite="mid:IA2PR13MB6563100AFC7E5D7C161A9F6395482@IA2PR13MB6563.namprd13.prod.outlook.com">
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta name="Generator"
content="Microsoft Word 15 (filtered medium)">
<style>@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
{mso-style-priority:34;
margin-top:0in;
margin-right:0in;
margin-bottom:0in;
margin-left:.5in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}span.EmailStyle17
{mso-style-type:personal-compose;
font-family:"Calibri",sans-serif;
color:black;
font-weight:normal;
font-style:normal;}.MsoChpDefault
{mso-style-type:export-only;
font-family:"Calibri",sans-serif;}div.WordSection1
{page:WordSection1;}ol
{margin-bottom:0in;}ul
{margin-bottom:0in;}</style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
<div class="WordSection1">
<p class="MsoNormal"><span style="font-size:14.0pt;color:black">What
has gotten into the USPTO?<o:p></o:p></span></p>
[...]<span style="font-size:14.0pt;color:black"><o:p></o:p></span>
<p class="MsoListParagraph"
style="text-indent:-.25in;mso-list:l0 level1 lfo1"><!--[if !supportLists]--><span
style="font-size:14.0pt;color:black"><span
style="mso-list:Ignore">4)<span
style="font:7.0pt "Times New Roman"">
</span></span></span><!--[endif]--><span
style="font-size:14.0pt;color:black">Several PCT
applications filed, and 6 months later, they are still under
secrecy review.<o:p></o:p></span></p>
</div>
</blockquote>
<p>This problem is largely within the practitioner's power to
avoid. Simply file in RO/IB instead of RO/US.</p>
<p>First, if the invention was not made in the US, you don't need an
FFL to satisfy US security requirements anyway, so file in RO/IB.</p>
<p>Even if the invention was made in the US, barring some surprise
you already had an FFL in your US priority document. That FFL
makes it okay to file in RO/IB (assuming that you did not add
significant new matter). <br>
</p>
<p>Even if you added significant new matter, just plan ahead by a
week or two, and file the text of the to-be-filed PCT as a US
provisional, and likely as not you will seen an FFL in that filing
receipt. If so, then that makes it okay to file in RO/IB. And
also gives you a potent rules-based-IBR benefit.</p>
<p>See session 14 at
<a class="moz-txt-link-freetext" href="https://blog.oppedahl.com/the-2022-schwegman-advanced-pct-training/">https://blog.oppedahl.com/the-2022-schwegman-advanced-pct-training/</a>
. Free of charge.</p>
<p><br>
</p>
</body>
</html>